Literature DB >> 26066402

Peyronie's Disease: AUA Guideline.

Ajay Nehra1, Ralph Alterowitz1, Daniel J Culkin1, Martha M Faraday1, Lawrence S Hakim1, Joel J Heidelbaugh1, Mohit Khera1, Erin Kirkby1, Kevin T McVary1, Martin M Miner1, Christian J Nelson1, Hossein Sadeghi-Nejad1, Allen D Seftel1, Alan W Shindel1, Arthur L Burnett1.   

Abstract

PURPOSE: The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of Peyronie's disease.
MATERIALS AND METHODS: A systematic review of the literature using the PubMed®, EMBASE® and Cochrane databases (search dates 1/1/1965 to 1/26/15) was conducted to identify peer-reviewed publications relevant to the diagnosis and treatment of PD. The review yielded an evidence base of 303 articles after application of inclusion/exclusion criteria.
RESULTS: The systematic review was used to create guideline statements regarding treatment of PD. When sufficient evidence existed, the body of evidence for a particular treatment was assigned a strength rating of A (high quality evidence; high certainty), B (moderate quality evidence; moderate certainty), or C (low quality evidence; low certainty). Evidence-based statements of Strong, Moderate, or Conditional Recommendation were developed based on benefits and risks/burdens to patients. Additional consensus statements related to the diagnosis of PD are provided as Clinical Principles and Expert Opinions due to insufficient published evidence.
CONCLUSIONS: There is a continually expanding literature on PD; the Panel notes that this document constitutes a clinical strategy and is not intended to be interpreted rigidly. The most effective approach for a particular patient is best determined by the individual clinician and patient in the context of that patient's history, values, and goals for treatment. As the science relevant to PD evolves and improves, the strategies presented here will be amended to remain consistent with the highest standards of clinical care.
Copyright © 2015 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  fibrosis; penile induration; penis

Mesh:

Year:  2015        PMID: 26066402      PMCID: PMC5027990          DOI: 10.1016/j.juro.2015.05.098

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  18 in total

1.  Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy.

Authors:  W L Furlow; H E Swenson; R E Lee
Journal:  J Urol       Date:  1975-07       Impact factor: 7.450

2.  Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease.

Authors:  Wayne J G Hellstrom; Muammer Kendirci; Richard Matern; Yolanda Cockerham; Leann Myers; Suresh C Sikka; Dennis Venable; Stanton Honig; Andrew McCullough; Lawrence S Hakim; Ajay Nehra; Lance E Templeton; Jon L Pryor
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

3.  Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial.

Authors:  A Palmieri; C Imbimbo; M Creta; P Verze; F Fusco; V Mirone
Journal:  Int J Androl       Date:  2011-11-15

4.  The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease.

Authors:  Muammer Kendirci; Mustafa F Usta; Richard V Matern; Sepehr Nowfar; Suresh C Sikka; Wayne J G Hellstrom
Journal:  J Sex Med       Date:  2005-09       Impact factor: 3.802

5.  Verapamil versus saline in electromotive drug administration for Peyronie's disease: a double-blind, placebo controlled trial.

Authors:  Jason M Greenfield; Sneha J Shah; Laurence A Levine
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

Review 6.  Psychological impact of Peyronie's disease: a review.

Authors:  Christian J Nelson; John P Mulhall
Journal:  J Sex Med       Date:  2012-11-15       Impact factor: 3.802

Review 7.  Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies.

Authors:  Martin Gelbard; Irwin Goldstein; Wayne J G Hellstrom; Chris G McMahon; Ted Smith; James Tursi; Nigel Jones; Gregory J Kaufman; Culley C Carson
Journal:  J Urol       Date:  2013-01-31       Impact factor: 7.450

8.  Extracorporeal shock wave therapy in Peyronie's disease: results of a placebo-controlled, prospective, randomized, single-blind study.

Authors:  Georgios Hatzichristodoulou; Christoph Meisner; Jürgen E Gschwend; Arnulf Stenzl; Sven Lahme
Journal:  J Sex Med       Date:  2013-07-30       Impact factor: 3.802

9.  Risk factors for emotional and relationship problems in Peyronie's disease.

Authors:  James F Smith; Thomas J Walsh; Simon L Conti; Paul Turek; Tom Lue
Journal:  J Sex Med       Date:  2008-07-14       Impact factor: 3.802

10.  The chronology of depression and distress in men with Peyronie's disease.

Authors:  Christian J Nelson; Chris Diblasio; Muammer Kendirci; Wayne Hellstrom; Patricia Guhring; John P Mulhall
Journal:  J Sex Med       Date:  2008-06-28       Impact factor: 3.802

View more
  70 in total

Review 1.  MRI of common penile pathologies and penile prostheses.

Authors:  Abdul-Rahman Abualruz; Ryan O'Malley; Janardhana Ponnatapura; Brenda L Holbert; Pat Whitworth; Rafel Tappouni; Neeraj Lalwani
Journal:  Abdom Radiol (NY)       Date:  2020-09

Review 2.  Nonsurgical treatment options in Peyronie's Disease: 2016 update.

Authors:  Raidh A Talib; Mohammed Abdulkareem Ibrahim; Önder Cangüven
Journal:  Turk J Urol       Date:  2016-12

3.  Collagenase Clostridium Histolyticum for the Treatment of Peyronie's Disease: A 'Real World' Clinical Perspective.

Authors:  James Anaissie; Wayne J G Hellstrom; Faysal A Yafi
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

Review 4.  Contemporary Review of Peyronie's Disease Treatment.

Authors:  Edward Capoccia; Laurence A Levine
Journal:  Curr Urol Rep       Date:  2018-05-17       Impact factor: 3.092

5.  2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature.

Authors:  Anthony J Bella; Jay C Lee; Ethan D Grober; Serge Carrier; Francois Benard; Gerald B Brock
Journal:  Can Urol Assoc J       Date:  2018-02-22       Impact factor: 1.862

Review 6.  Peyronie's Disease: Intralesional Therapy and Surgical Intervention.

Authors:  Louis A Aliperti; Akanksha Mehta
Journal:  Curr Urol Rep       Date:  2016-09       Impact factor: 3.092

Review 7.  Outcomes of Surgery in Peyronie's Disease Following Intralesional Collagenase Clostridium Histolyticum Injections.

Authors:  Mahdi Bazzi; Marcus L Jamil; Ali A Dabaja
Journal:  Curr Urol Rep       Date:  2019-06-14       Impact factor: 3.092

Review 8.  Intralesional collagenase Clostridium histolyticum in the management of Peyronie's disease: current best practice.

Authors:  Daniel J Cwikla; Faysal A Yafi
Journal:  Ther Adv Urol       Date:  2018-02-08

9.  Diagnosis and Treatment of Peyronie Disease With Both Dorsal and Ventral Plaques Using Doppler Ultrasound: NYU Case of the Month, July 2019.

Authors:  Seth D Cohen
Journal:  Rev Urol       Date:  2019

Review 10.  Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature.

Authors:  Ayad Yousif; Caleb Natale; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2021-01-08       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.